Drug Combination Details
| General Information of the Combination (ID: C00671) | |||||
|---|---|---|---|---|---|
| Name | 1-deoxynojirimycin NP Info | + | Indomethacin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Gastric ulcer
[ICD-11: DA60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | p105 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | A GU mouse model was induced by indomethacin | |||||
| Experimental
Result(s) |
DNJ showed protection for gastric functions of GU mice by reducing the levels of MOT and SP, and increasing the levels of SS and VIP. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway. Front Pharmacol. 2018 Apr 19;9:372. | |||
